Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL Treatment
Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement
Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi®) with gemcitabine and oxaliplatin (Glofit-GemOx) in the basic insurance package for adults with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplantation (auto-SCT). This February 12, 2026, reassessment—detailed in the Zorginstituut Nederland pakketadvies—overturns a prior negative advice based on phase III STARGLO data showing overall survival (OS) gains over rituximab-GemOx (R-GemOx), despite low evidence quality.
STARGLO Survival Gains vs. R-GemOx
STARGLO demonstrates median OS of 25.5 months (95% CI: 18.3-NR) for Glofit-GemOx versus 12.9 months (95% CI: 7.9-18.5) for R-GemOx (HR 0.62, 95% CI: 0.43-0.88), meeting PASKWIL criteria after adjustments. Therapeutic value tops chemo-immunotherapy (CIT), but list-price glofitamab cost-effectiveness yields ICER over €80,000/QALY (€94,584/QALY adjusted for Dutch age 73, generalized gamma PFS/log-logistic OS, 5-year progression-free costs, equal curative follow-ons).
Model Inputs Driving ICER
Partitioned survival analysis (45-year horizon, societal perspective) gives 3.92 QALYs for Glofit-GemOx versus 1.62 for R-GemOx (incremental 2.31 QALYs), with lifetime costs €318,147 versus €187,293 (incremental €130,855; €85,564 drug costs over 8.5 cycles). Base-case ICER (€94,584/QALY) incorporates Dutch age (+19%), conservative survival fits, 5-year monitoring (+13%), equal post-progression therapies (+15%), and age-aligned mortality. Probabilistic sensitivity (5,000 runs) shows 35% chance cost-effective at €80,000/QALY; EVPI €1,147/patient highlights data gaps.
Year-3 Budget and Safeguards
Year-3 uptake hits 131 patients (80-90% penetration in 2L+/non-curative lines from 1,616 annual DLBCL cases), with €12.0M gross spend (€91,978/patient) offset by €10.4M CIT savings, netting €10.7M. Safeguards include national registry for bispecific outcomes, use agreements, and 3-4 year evidence review on OS/age effects. Obinutuzumab covers CRS mitigation; failure risks exceed proportionality thresholds.
Pricing Mandates
Glofit-GemOx addresses unmet R/R DLBCL needs (10-15% refractory, 20-30% relapse post-R-CHOP; 6-12 month survival), advancing bispecifics amid CAR-T shifts. Glofitamab cost-effectiveness requires 28% discount to hit €80,000/QALY, enabling real-world HOVON data for iterative reviews versus evolving options like less-toxic CAR-T or monotherapy. Sluis mechanisms balance €12M oncology spend with fiscal sustainability.
